Methylecgonine

Identification

Name
Methylecgonine
Accession Number
DB04688
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • Ecgonine methyl ester
Categories
UNII
Y35FJB3QBJ
CAS number
7143-09-1
Weight
Average: 199.2469
Monoisotopic: 199.120843415
Chemical Formula
C10H17NO3
InChI Key
QIQNNBXHAYSQRY-UYXSQOIJSA-N
InChI
InChI=1S/C10H17NO3/c1-11-6-3-4-7(11)9(8(12)5-6)10(13)14-2/h6-9,12H,3-5H2,1-2H3/t6-,7+,8-,9+/m0/s1
IUPAC Name
methyl (1R,2R,3S,5S)-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
SMILES
[H][[email protected]@]12CC[[email protected]@]([H])(N1C)[[email protected]@]([H])(C(=O)OC)[[email protected]@]([H])(O)C2

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UIg gamma-2 chain C regionNot AvailableHuman
UIg kappa chain C regionNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methylecgonine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methylecgonine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methylecgonine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methylecgonine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methylecgonine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methylecgonine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methylecgonine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylecgonine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methylecgonine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Azaperone.Investigational, Vet Approved
AzelastineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Methylecgonine.Illicit
BenmoxinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methylecgonine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methylecgonine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methylecgonine.Approved, Investigational
BuprenorphineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methylecgonine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methylecgonine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methylecgonine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methylecgonine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methylecgonine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methylecgonine.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methylecgonine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methylecgonine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methylecgonine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methylecgonine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methylecgonine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylecgonine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methylecgonine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Methylecgonine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methylecgonine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methylecgonine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methylecgonine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methylecgonine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methylecgonine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methylecgonine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methylecgonine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methylecgonine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methylecgonine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methylecgonine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methylecgonine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methylecgonine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methylecgonine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methylecgonine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methylecgonine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methylecgonine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methylecgonine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Methylecgonine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methylecgonine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methylecgonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methylecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methylecgonine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methylecgonine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methylecgonine.Approved
EthanolMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methylecgonine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methylecgonine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methylecgonine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylecgonine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methylecgonine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methylecgonine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methylecgonine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methylecgonine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methylecgonine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methylecgonine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylecgonine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methylecgonine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methylecgonine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fospropofol.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methylecgonine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methylecgonine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Methylecgonine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methylecgonine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylecgonine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methylecgonine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methylecgonine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methylecgonine.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Hydracarbazine.Experimental
HydrocodoneMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methylecgonine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Indiplon.Investigational
IproclozideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Iproniazid.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methylecgonine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methylecgonine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methylecgonine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methylecgonine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methylecgonine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methylecgonine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methylecgonine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methylecgonine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methylecgonine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylecgonine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methylecgonine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methylecgonine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methylecgonine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methylecgonine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methylecgonine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methylecgonine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methylecgonine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methylecgonine.Approved
MethotrimeprazineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methylecgonine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methylecgonine.Approved
MetyrosineMethylecgonine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methylecgonine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved, Investigational
MirtazapineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methylecgonine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methylecgonine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methylecgonine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Nefazodone.Approved, Withdrawn
NialamideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Nialamide.Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methylecgonine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methylecgonine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methylecgonine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methylecgonine.Approved
OpiumThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Opium.Approved, Illicit
OrphenadrineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methylecgonine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methylecgonine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methylecgonine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methylecgonine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methylecgonine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methylecgonine.Approved
ParaldehydeMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methylecgonine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methylecgonine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved
PerazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methylecgonine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methylecgonine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methylecgonine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenoxypropazine.Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methylecgonine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pirlindole.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pomalidomide.Approved
PramipexoleMethylecgonine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Methylecgonine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methylecgonine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methylecgonine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methylecgonine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylecgonine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methylecgonine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methylecgonine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methylecgonine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Methylecgonine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methylecgonine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylecgonine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methylecgonine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methylecgonine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methylecgonine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylecgonine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Romifidine.Vet Approved
RopiniroleMethylecgonine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methylecgonine.Approved
RotigotineMethylecgonine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methylecgonine.Approved
SafrazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methylecgonine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methylecgonine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methylecgonine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methylecgonine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Sultopride.Experimental
SuvorexantMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methylecgonine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tetrodotoxin.Investigational
ThalidomideMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methylecgonine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methylecgonine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylecgonine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methylecgonine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methylecgonine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methylecgonine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methylecgonine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methylecgonine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methylecgonine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methylecgonine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylecgonine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methylecgonine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methylecgonine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylecgonine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Zolazepam.Vet Approved
ZolpidemMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methylecgonine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylecgonine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
104904
PubChem Substance
46509033
ChemSpider
94674
BindingDB
50417947
ChEBI
31529
ChEMBL
CHEMBL1232472
HET
ECG
PDB Entries
2ajy / 2ajz

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility587.0 mg/mLALOGPS
logP0.14ALOGPS
logP-0.21ChemAxon
logS0.47ALOGPS
pKa (Strongest Acidic)14.6ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity51.34 m3·mol-1ChemAxon
Polarizability21.05 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7991
Blood Brain Barrier+0.8824
Caco-2 permeable+0.748
P-glycoprotein substrateNon-substrate0.5304
P-glycoprotein inhibitor INon-inhibitor0.5359
P-glycoprotein inhibitor IINon-inhibitor0.9815
Renal organic cation transporterNon-inhibitor0.5248
CYP450 2C9 substrateNon-substrate0.7808
CYP450 2D6 substrateNon-substrate0.7909
CYP450 3A4 substrateSubstrate0.6138
CYP450 1A2 substrateNon-inhibitor0.8409
CYP450 2C9 inhibitorNon-inhibitor0.9527
CYP450 2D6 inhibitorNon-inhibitor0.8729
CYP450 2C19 inhibitorNon-inhibitor0.9477
CYP450 3A4 inhibitorNon-inhibitor0.9848
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9855
Ames testNon AMES toxic0.754
CarcinogenicityNon-carcinogens0.9624
BiodegradationReady biodegradable0.5936
Rat acute toxicity2.6061 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9177
hERG inhibition (predictor II)Non-inhibitor0.9158
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tropane alkaloids. These are organic compounds containing the nitrogenous bicyclic alkaloid parent N-Methyl-8-azabicyclo[3.2.1]octane.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Tropane alkaloids
Sub Class
Not Available
Direct Parent
Tropane alkaloids
Alternative Parents
Piperidinecarboxylic acids / Beta hydroxy acids and derivatives / N-alkylpyrrolidines / Methyl esters / Trialkylamines / Secondary alcohols / Cyclic alcohols and derivatives / Amino acids and derivatives / Monocarboxylic acids and derivatives / Azacyclic compounds
show 4 more
Substituents
Piperidinecarboxylic acid / Tropane alkaloid / Beta-hydroxy acid / Hydroxy acid / Piperidine / N-alkylpyrrolidine / Methyl ester / Pyrrolidine / Cyclic alcohol / Amino acid or derivatives
show 19 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, tropane alkaloid, methyl ester (CHEBI:31529)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Immunoglobulin receptor binding
Specific Function
Not Available
Gene Name
IGHG2
Uniprot ID
P01859
Uniprot Name
Ig gamma-2 chain C region
Molecular Weight
35900.445 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Immunoglobulin receptor binding
Specific Function
Not Available
Gene Name
IGKC
Uniprot ID
P01834
Uniprot Name
Ig kappa chain C region
Molecular Weight
11608.765 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 11, 2007 11:49 / Updated on December 01, 2017 15:31